Teplizumab FDA Approval Status
Last updated by Judith Stewart, BPharm on March 8, 2021.
FDA Approved: No
Generic name: teplizumab
Company: Provention Bio, Inc.
Treatment for: Prevention of Type 1 Diabetes
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) in development for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals.
Development timeline for teplizumab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.